Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer

Analysis of the National Cancer Data Base

Waqar Haque, Vivek Verma, Mohamad Fakhreddine, Sandra Hatch, E. Brian Butler, Bin S. Teh

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose The standard treatment for stage IB1 and IIA1 cervical carcinoma is surgery. For non-operative cases, the National Comprehensive Cancer Network recommends definitive radiotherapy (RT) with or without chemotherapy. This study sought to determine whether the addition of chemotherapy to RT improved overall survival (OS) for patients with stage IB1 and IIA1 cervical cancer. Methods We used the National Cancer Data Base to identify patients with stage IB1 or stage IIA1 cervical cancer diagnosed in 2004 to 2012 who received definitive RT with or without chemotherapy. Patient, tumor, and treatment facility characteristics were assessed. Kaplan-Meier analysis was performed to compare overall survival (OS) between groups. Cox regression analysis was performed to identify factors associated with survival. Propensity-score matching was used to compare survival outcomes while accounting for indication bias. Results 825 patients met the specified criteria. 275 (33.3%) of patients received treatment with RT alone, whereas 550 (66.7%) were treated with CRT. The median OS in patients treated with RT alone was 121.1 months, while the median OS for patients treated with CRT was not reached (hazard ratio [HR] = 0.719; 95% confidence interval [CI] 0.549–0.945). Propensity-score matched analysis confirmed that CRT was superior to RT alone (HR = 0.701; 95% CI 0.509 to 0.963). Conclusions Our study suggests the addition of chemotherapy to definitive RT in patients with stage IB1 or stage IIA1 cervical cancer is associated with an improvement in OS. Prospective studies are recommended to validate these results and to further investigate the quality of life differences associated with chemotherapy use.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalGynecologic Oncology
Volume144
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Uterine Cervical Neoplasms
Radiotherapy
Databases
Drug Therapy
Survival
Neoplasms
Propensity Score
Confidence Intervals
Kaplan-Meier Estimate
Therapeutics
Regression Analysis
Quality of Life
Prospective Studies
Carcinoma

Keywords

  • Cervical cancer
  • Cervix
  • Chemotherapy
  • Hysterectomy
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer : Analysis of the National Cancer Data Base. / Haque, Waqar; Verma, Vivek; Fakhreddine, Mohamad; Hatch, Sandra; Butler, E. Brian; Teh, Bin S.

In: Gynecologic Oncology, Vol. 144, No. 1, 01.01.2017, p. 28-33.

Research output: Contribution to journalArticle

Haque, Waqar ; Verma, Vivek ; Fakhreddine, Mohamad ; Hatch, Sandra ; Butler, E. Brian ; Teh, Bin S. / Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer : Analysis of the National Cancer Data Base. In: Gynecologic Oncology. 2017 ; Vol. 144, No. 1. pp. 28-33.
@article{6bb89ecbf2f3464fb63a6ffad476a0c2,
title = "Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base",
abstract = "Purpose The standard treatment for stage IB1 and IIA1 cervical carcinoma is surgery. For non-operative cases, the National Comprehensive Cancer Network recommends definitive radiotherapy (RT) with or without chemotherapy. This study sought to determine whether the addition of chemotherapy to RT improved overall survival (OS) for patients with stage IB1 and IIA1 cervical cancer. Methods We used the National Cancer Data Base to identify patients with stage IB1 or stage IIA1 cervical cancer diagnosed in 2004 to 2012 who received definitive RT with or without chemotherapy. Patient, tumor, and treatment facility characteristics were assessed. Kaplan-Meier analysis was performed to compare overall survival (OS) between groups. Cox regression analysis was performed to identify factors associated with survival. Propensity-score matching was used to compare survival outcomes while accounting for indication bias. Results 825 patients met the specified criteria. 275 (33.3{\%}) of patients received treatment with RT alone, whereas 550 (66.7{\%}) were treated with CRT. The median OS in patients treated with RT alone was 121.1 months, while the median OS for patients treated with CRT was not reached (hazard ratio [HR] = 0.719; 95{\%} confidence interval [CI] 0.549–0.945). Propensity-score matched analysis confirmed that CRT was superior to RT alone (HR = 0.701; 95{\%} CI 0.509 to 0.963). Conclusions Our study suggests the addition of chemotherapy to definitive RT in patients with stage IB1 or stage IIA1 cervical cancer is associated with an improvement in OS. Prospective studies are recommended to validate these results and to further investigate the quality of life differences associated with chemotherapy use.",
keywords = "Cervical cancer, Cervix, Chemotherapy, Hysterectomy, Radiation therapy",
author = "Waqar Haque and Vivek Verma and Mohamad Fakhreddine and Sandra Hatch and Butler, {E. Brian} and Teh, {Bin S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2016.10.033",
language = "English (US)",
volume = "144",
pages = "28--33",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer

T2 - Analysis of the National Cancer Data Base

AU - Haque, Waqar

AU - Verma, Vivek

AU - Fakhreddine, Mohamad

AU - Hatch, Sandra

AU - Butler, E. Brian

AU - Teh, Bin S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose The standard treatment for stage IB1 and IIA1 cervical carcinoma is surgery. For non-operative cases, the National Comprehensive Cancer Network recommends definitive radiotherapy (RT) with or without chemotherapy. This study sought to determine whether the addition of chemotherapy to RT improved overall survival (OS) for patients with stage IB1 and IIA1 cervical cancer. Methods We used the National Cancer Data Base to identify patients with stage IB1 or stage IIA1 cervical cancer diagnosed in 2004 to 2012 who received definitive RT with or without chemotherapy. Patient, tumor, and treatment facility characteristics were assessed. Kaplan-Meier analysis was performed to compare overall survival (OS) between groups. Cox regression analysis was performed to identify factors associated with survival. Propensity-score matching was used to compare survival outcomes while accounting for indication bias. Results 825 patients met the specified criteria. 275 (33.3%) of patients received treatment with RT alone, whereas 550 (66.7%) were treated with CRT. The median OS in patients treated with RT alone was 121.1 months, while the median OS for patients treated with CRT was not reached (hazard ratio [HR] = 0.719; 95% confidence interval [CI] 0.549–0.945). Propensity-score matched analysis confirmed that CRT was superior to RT alone (HR = 0.701; 95% CI 0.509 to 0.963). Conclusions Our study suggests the addition of chemotherapy to definitive RT in patients with stage IB1 or stage IIA1 cervical cancer is associated with an improvement in OS. Prospective studies are recommended to validate these results and to further investigate the quality of life differences associated with chemotherapy use.

AB - Purpose The standard treatment for stage IB1 and IIA1 cervical carcinoma is surgery. For non-operative cases, the National Comprehensive Cancer Network recommends definitive radiotherapy (RT) with or without chemotherapy. This study sought to determine whether the addition of chemotherapy to RT improved overall survival (OS) for patients with stage IB1 and IIA1 cervical cancer. Methods We used the National Cancer Data Base to identify patients with stage IB1 or stage IIA1 cervical cancer diagnosed in 2004 to 2012 who received definitive RT with or without chemotherapy. Patient, tumor, and treatment facility characteristics were assessed. Kaplan-Meier analysis was performed to compare overall survival (OS) between groups. Cox regression analysis was performed to identify factors associated with survival. Propensity-score matching was used to compare survival outcomes while accounting for indication bias. Results 825 patients met the specified criteria. 275 (33.3%) of patients received treatment with RT alone, whereas 550 (66.7%) were treated with CRT. The median OS in patients treated with RT alone was 121.1 months, while the median OS for patients treated with CRT was not reached (hazard ratio [HR] = 0.719; 95% confidence interval [CI] 0.549–0.945). Propensity-score matched analysis confirmed that CRT was superior to RT alone (HR = 0.701; 95% CI 0.509 to 0.963). Conclusions Our study suggests the addition of chemotherapy to definitive RT in patients with stage IB1 or stage IIA1 cervical cancer is associated with an improvement in OS. Prospective studies are recommended to validate these results and to further investigate the quality of life differences associated with chemotherapy use.

KW - Cervical cancer

KW - Cervix

KW - Chemotherapy

KW - Hysterectomy

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84992458968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992458968&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.10.033

DO - 10.1016/j.ygyno.2016.10.033

M3 - Article

VL - 144

SP - 28

EP - 33

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -